Synta Pharmaceuticals: To buy or not to buy?

Posted on March 30th, 2007 by Brian

After the exhaustive analysis of Synta Pharmaceuticals, it’s time to make the call to buy the stock or put it on the watch list (I haven’t seen any real red flags that would lead me to throw it out completely).

My biggest concern is with their cash flow. Even with the cash from the IPO, Synta is going to run out of money sooner rather than later. In fact, their CEO, Safi R. Bahcall, said in a slide show talk at the Lehman Brothers Global Healthcare Conference (free registration required) that they were planning on finding a partner in 2007. Depending on the deal, I could see a partnership sending the stock price in either direction. Certainly the more desperate they are (due to lack of money), the more likely they’ll take a partnership that is giving away more of the potential profits than the stock holders would like.

Synta’s IPO was fairly recent, so there’s potential for the initial (private equity) investors to liquidate some of their position, but, some of the major early investors were buying additional shares at the IPO, so the end of the lock up agreement is probably not a major concern. At any rate, I’ll keep an eye on the 28 million shares that will be available for sale after the lock up agreement concludes (180 days from Feb 6th, 2007 which is August 5th if I counted correctly). There are some potential extensions of the lock-up agreement if there are earnings calls prior to the agreement, so that date has potential to change.

Here’s my predictions for the stock:

    First quarterly report-I’d imagine this will continue to say they’ll run out of money in mid-2008 so there won’t be much change in stock price. UPDATE:It came out two days ago: As of Jan 1st, they had $91.5 million in the bank (including $44.7 from the IPO after expenses) and they had a burn rate of $57.2 million for 2006. Given that the clinical trial will cost $22-24 million, their burn rate will likely be higher in 2007, and my mid-2008 prediction for them to run out of money looks on target. The stock didn’t really move on the earnings announcement (although there was a big (7%) drop at the close today on a large volume, but no news as far as I can tell).
    Phase 3 clinical trial for treating melanomas with STA-4783 announced-I’ll bet there’s an unjustified small bump in price just because people like to see progress, even if it’s on target progress.
    Partnership-It will result in a large boost in stock price. It will alleviate fears that they’ll run out of money and give support to their product since it means other scientists think that their product will work. The biggest question is when this will happen.  Look for the stock price to head down slowly until the partnership occurs.

So, I think I’m going to take a wait and see approach. The problem is really in the cash flow and Synta really needing a partnership to complete their clinical trial. We could bet on them getting one sooner rather than later, but I prefer to bet on good science rather than the managements ability to make partnerships.

I’ll revisit the stock after their first quarter 2007 report when I can get a better idea of their current cash flow.

Filed under: Synta Pharmaceuticals (SNTA)

« What’s the Market for Drugs in Synta Pharmaceuticals (SNTA) Pipeline Look Like? Back to the Basics: The Building Blocks of the Cells (and drugs that affect them) »

18 Responses to “Synta Pharmaceuticals: To buy or not to buy?”

  1. TJP, on March 30th, 2007 at 9:02 pm Said:

    Your complete analysis was very enlightening. Here’s my 2 cents on SNTA:

    The stock looks promising, yet extremely volatile. Whether or not this stock gets a drug approved, it appears to be ready for a sudden movement ( lost 7% as I write this). So why not profit from the unpredictable movement using a long straddle?

    Small cap stocks like these are always highly active, especially when drug approvals are near. I’m thinking about trading some options.

    So whose next on your review list? I’m very curious.

  2. What’s yours is mine: Rosetta Genomics partners, on April 11th, 2007 at 12:29 pm Said:

    […] analyzing Synta, I decided to take a pass on buying their stock right now because I was worried that there wouldn’t be anyone to partner with them; Rosetta […]

  3. Hili, on May 2nd, 2007 at 3:28 am Said:

    Hello,

    Interesting report.

    Will SNTA’s P3 endpoint be PFS or OS (overall survival)? What is the real merit in increasing PFS while not effecting OS?

    Feel free to email me - I am looking for new bio investments

    Best,
    H.

  4. Brian, on May 2nd, 2007 at 8:04 am Said:

    I believe it will be PFS with OS as a secondary endpoint. They’ll report the PFS earlier because it requires more time to become statistically significant.

    Here’s my take on Progression free survival in case you didn’t see it.

  5. Brian, on May 2nd, 2007 at 10:32 am Said:

    “it requires” should read OS requires.

  6. Joey, on October 24th, 2007 at 9:46 pm Said:

    GLAXO - $1billion agreement - Done Deal - Any Questions?

  7. How to Get Six Pack Fast, on April 15th, 2009 at 6:51 am Said:

    After reading through this article, I just feel that I really need more information on the topic. Can you suggest some resources please?

  8. Walton, on May 27th, 2009 at 3:27 am Said:

    toller artikel, muss ich gleich mal bookmarken :)

  9. Zingaro, on May 28th, 2009 at 6:07 pm Said:

    can that be true? i mean seriously?! what the..

  10. Northrup, on May 29th, 2009 at 7:50 pm Said:

    i couldnt agree more :) have to bookmark this article

  11. watch the pacific online streaming, on August 10th, 2010 at 6:09 pm Said:

    Did you check your site in IE6? Looks a bit weird

  12. freundin suchen, on October 22nd, 2010 at 4:45 am Said:

    Ich würde meinen.. dass das irgendwie gut ist. Naja muß jeder das für sich selber überlegen wie man sich entscheidet..

  13. Shirly Scholer, on December 18th, 2010 at 1:43 pm Said:

    There is some thoughtful views in these comments, it makes a pleasant change to browse through such intelligent wording, and makes you want to respond to the discussion.

    Regards

    Webmaster hoover upright vacuum

  14. straddle trader pro, on June 9th, 2011 at 11:48 pm Said:

    I’m joyful to find your distinguished way of writing and lately finished studying by means of your weblog and I’m very impressed. I do have a couple questions for you personally however. Do you suppose you are fascinated by doing a observe-up posting about this? Will you be going to maintain bringing up-to-date as nicely?

  15. belly fat, on July 5th, 2011 at 5:10 pm Said:

    Hiya, I’m really glad I’ve found this info. Today bloggers publish only about gossips and web and this is actually frustrating. A good site with exciting content, that’s what I need. Thank you for keeping this website, I will be visiting it. Do you do newsletters? Cant find it.

  16. seo delray beach, on July 7th, 2011 at 3:14 am Said:

    Really completely happy I got here across this weblog post. It was extremely useful. Anyhow, I was wondering what kind of theme you’re utilizing? I like the colours as a result of they blend so good. Effectively, sustain the great articles and I’ll come back. I am completely going to inform others about this.

  17. honest web business, on July 28th, 2011 at 8:07 pm Said:

    I like the valuable info you provide in your articles. I’ll bookmark your weblog and check again here frequently. I am quite sure I’ll learn many new stuff right here! Best of luck for the next!

  18. Benefits of Yoga, on July 29th, 2011 at 7:22 am Said:

    I like seeing web sites that postulate the abetment of supplying a nature tip helpful useful resource in that unshackle. profuse thanks since this glorious rudiment of data about info

Leave a Reply